American Journal of Hematology, Volume 101, Issue 4, Page 794-806, April 2026.ABSTRACT Postpartum hemorrhage (PPH) remains the leading cause of preventable maternal mortality despite standard interventions. Recent fibrinogen trials failed to improve outcomes, prompting interest in coagulation factor XIII (FXIII). FXIII functions as “molecular cement,” cross‐linking fibrin and stabilizing clots.
Jeremy W. Jacobs +8 more
wiley +1 more source
Endovascular thrombectomy versus intravenous tissue plasminogen activator for vertebrobasilar stroke treatment: insights from the national inpatient sample. [PDF]
Front NeurolSaha R +6 more
europepmc +1 more source
Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.Abstract INTRODUCTION Hyperhomocysteinemia represents a modifiable risk factor for cognitive decline and dementia, yet the role of epigenetic aging mechanisms in mediating this association remain poorly characterized, limiting development of targeted interventions.
Haoxuan Li +11 more
wiley +1 more source
Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.Abstract In 2011, a workgroup of the Alzheimer's Association Research Roundtable introduced recommendations for detecting and monitoring amyloid‐related imaging abnormalities (ARIA) in Alzheimer's disease (AD) clinical trials. Since then, anti‐amyloid immunotherapies have received regulatory approval for AD treatment and are beginning to enter clinical
Ellis S. van Etten +14 more
wiley +1 more source
Tissue plasminogen activator associated pulmonary hemorrhage in patient with ACTA2-associated arteriopathy. [PDF]
J Vasc Surg Cases Innov TechHughes TG, Wurth MA, Sheppard MB.
europepmc +1 more source
Use of anti–amyloid‐β monoclonal antibodies in persons with Down syndrome Alzheimer's disease
Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.Abstract INTRODUCTION The recent development and licensing of anti–amyloid‐β monoclonal antibodies for the treatment of early‐stage Alzheimer's disease have significantly shifted the clinical landscape. However, current use recommendations preclude the administration of these new drugs to persons who have Down syndrome.
Clíona Farrell +5 more
wiley +1 more source
A meta-analysis on racial disparity in administration of tissue plasminogen activator (tPA) in stroke patients. [PDF]
Health Sci RepLarik MO, Bhattarai P.
europepmc +1 more source
Association of Eosinophil Counts and Ratios With Clinical Outcomes After Acute Ischemic Stroke
Brain and Behavior, Volume 16, Issue 4, April 2026.This study demonstrates for the first time that low peripheral eosinophil levels are independent predictors of adverse 5‐year outcomes in ischemic stroke or TIA patients, providing a novel basis for risk stratification and future mechanistic research.
Yangying Lu +12 more
wiley +1 more source
Correction: Usefulness of carotid duplex ultrasonography in predicting residual large-vessel occlusions after intravenous recombinant tissue plasminogen activator therapy in patients with acute ischemic stroke. [PDF]
J Med Ultrason (2001)Kaburagi K +9 more
europepmc +1 more source
Cancer Medicine, Volume 15, Issue 4, April 2026.ABSTRACT Metastatic castration‐resistant prostate cancer (mCRPC) is the most aggressive kind of prostate cancer (PCa). Because the traditional taxane‐based therapy is ineffective, cabazitaxel (CBZ), a second‐generation, semisynthetic taxane, has been developed.
Roberta Arpino +7 more
wiley +1 more source